se of mobile phone TEXT messages to increase the adherence of SGLT2 Inhibitors: a MULti-country Effectiveness-Implementation trial (TEXT-STIMULI)

Not Applicable

• Conditions: Adherence to medication use of sodium–glucose co-transporter-2 (SGLT2) inhibitors.; Renal and Urogenital - Kidney disease; Cardiovascular - Coronary heart disease; Metabolic and Endocrine - Diabetes

• Registration Number: ACTRN12622001500741
• Lead Sponsor: The University of Sydney

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2022-11-30
• Last Update Posted: 5 December 2022

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: All
• Target Recruitment: 476

Inclusion Criteria

An indication for SGLT2 Inhibitor (as per Australian and Canadian guidelines at time of assessment).
Receiving a first, and ongoing, prescription for an SGLT2 Inhibitor.
Access to an operational smart mobile telephone that can send and receive text messages, open multimedia files, and access the Internet.
Sufficient English language proficiency to read and understand text messages on a mobile telephone.
Willing and able to perform trial related procedures.

Exclusion Criteria

Life expectancy less than 12 months.
Already prescribed an SGLT2i more than 3 months prior to assessment.
Diagnosed with Type 1 diabetes mellitus or gestational diabetes.

Study & Design

• Study Type: Interventional
• Study Design: Not specified